Form 4: Director Timothy Walbert Exercises Mirum Stock Units

Mirum Pharmaceuticals Director Timothy Walbert acquired 3,977 shares of common stock through the vesting of restricted stock units.

Summary

• Director Timothy P. Walbert acquired 3,977 shares of Mirum Pharmaceuticals (MIRM) common stock.
• The acquisition resulted from the vesting of restricted stock units (RSUs) on May 29, 2026.
• Following the transaction, the director holds a total of 9,680 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, representing standard equity compensation vesting for a company director.

Positives

• Director maintains a direct equity stake in the company, aligning interests with shareholders.

Negatives

• None identified.

Risks

• None identified.

Future Outlook

Not applicable as this is a routine insider transaction filing.

Industry Context

StockSavvy.ai notes that routine RSU vesting for directors is a standard component of executive compensation packages in the biotechnology sector and does not typically signal a change in strategic direction.

Comparison to Industry Standards

• The transaction follows standard corporate governance practices for equity-based compensation in the pharmaceutical industry.

Stakeholder Impact

• Minimal impact on shareholders as this is a routine equity compensation event.

Key Dates

Keywords

MIRM, Mirum Pharmaceuticals, Insider Trading, Form 4, Equity Compensation